Sweden, March 25, 2020
Bactiguard launched the disinfectant HYDROCYN aqua® in Sweden at the beginning of March and, since then, demand has been high. As late as this weekend, products were flown in from the company’s production facility in Malaysia via a newly established air bridge. Now, work is in progress to start production in Sweden as well.
“In times like these, efficient logistics is extremely important in providing patients, healthcare providers and other critical societal functions with protective medical supplies. To ensure that we can meet the needs in the Swedish and European markets, we are now preparing to start up production at Bactiguard’s facility in Tullinge,” says Jonas Östregård, SVP Sales & Marketing.
“We received permission from the Swedish Chemicals Agency last Friday. The matter was dealt with very quickly due to the lack of disinfectants in the market. If everything goes according to plan, we hope to be able to get started within a couple of weeks, which would mean a substantial increase in capacity and the opportunity to launch the product in more markets,” Jonas Östregård continues.
HYDROCYN aqua® is a pH neutral and water-based solution for hand disinfection, surface disinfection and wound wash which has demon¬strated a significant effect in inactivating previous variants of coronavirus within 15 seconds. Unlike alcohol and chlorhexidine, it isn’t irritating, toxic or harmful to the body. The active substance is hypochlorous acid (HOCI). The product is CE marked (EU approved) and registered by the FDA in the US. For the time being, it is produced at the company’s production facility in Malaysia and then flown or shipped to Sweden.
For further information, please contact:
Cecilia Edström, CEO, phone +46 440 58 80
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.
Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.
Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives at www.bactiguard.com
This information was brought to you by Cision
